Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
- Disease/Condition
- Acute Myocardial Infarction
- Drug/Device/Intervention
- Suxiao Jiuxin Pills
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Xiaolu Li
- Funder
- Qianfoshan Hospital
- Location
- Jinan, China
- Phase
- Phase 4
- Start date
- Aug 01, 2022
- End date
- Jun 01, 2027
- Enrollment
- 116 participants
Changes of MMP-9
The incidence of cardiovascular disease is still high in China under the condition of
 non-standard treatment of Western medicine. Acute coronary plaque rupture and thrombosis is
 an extreme manifestation of instability of vulnerable plaque, which is the result of the
 joint action of multiple factors. The intervention of unstable plaque reversal from multiple
 factors is inherently reasonable. Compared with the treatment of thrombosis and unstable
 plaque in western medicine, quick acting Jiuxin Pill can not only calm and relieve pain for
 pain and other symptoms, but also regulate immune inflammation and metabolic disorder,
 improve microcirculation and anti myocardial ischemia. In order to evaluate the efficacy,
 safety and modern scientific basis of Suxiao Jiuxin Pill in acute myocardial infarction
 (AMI), the investigators designed this study.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05466968
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05466968 through Pure Global AI's free database. This Phase 4 trial is sponsored by Xiaolu Li and is currently Not yet recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 116 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.